| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 526.31 | 9.5% |
| Total Income | 537.55 | 8.2% |
| Expenditure | 462.49 | 12.1% |
| PBT | 74.70 | 4.8% |
| Net Profit | 55.83 | 4.2% |
| OPM | 15.34% | 1.45pp |
| NPM | 10.39% | 1.34pp |
| EPS | 22.33 | 4.2% |
AstraZeneca Pharma India Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies
14 Aug 2025 · 14 Aug 2025, 02:13 pm
Summary
AstraZeneca Pharma India Ltd has reported its financial results for the quarter ended June 30, 2025. The company's revenue from operations stands at 5,263.1 million, with a total income of 5,376.5 million. The total expenses amounted to 4,624.9 million, leading to a profit before exceptional items and tax of 780.6 million. After tax, the profit stands at 582.5 million. The company has identified 'Healthcare Segment' as its only reportable segment. The operations at the manufacturing site have ceased and the plant and machinery are fully depreciated. The company has made an announcement to exit the manufacturing site in Bangalore.
Key Highlights
- 1
Revenue from operations: 5,263.1 million
- 2
Total income: 5,376.5 million
- 3
Total expenses: 4,624.9 million
- 4
Profit before exceptional items and tax: 780.6 million
- 5
Profit after tax: 582.5 million
- 6
Healthcare Segment as the only reportable segment
- 7
Manufacturing site operations ceased
- 8
Plant and machinery fully depreciated
- 9
Intention to exit the manufacturing site in Bangalore
Management Comments
Praveen Rao Akkinepally
The Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2025. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2025.
Informational and educational content only. Not investment advice.